{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:40:24Z","timestamp":1793814024659,"version":"4.6.1"},"reference-count":35,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.2967\/jnumed.122.264857","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T16:40:19Z","timestamp":1667493619000},"page":"611-617","source":"Crossref","is-referenced-by-count":31,"title":["A Single-Arm, Low-Dose, Prospective Study of\n                    <sup>177<\/sup>\n                    Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"64","author":[{"given":"Guochang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"2023040307200706000_64.4.611.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023040307200706000_64.4.611.2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet."},{"key":"2023040307200706000_64.4.611.3","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","article-title":"177Lu-PSMA-617 versus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial","volume":"49","author":"Satapathy","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.4","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00068-4"},{"key":"2023040307200706000_64.4.611.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.147413"},{"key":"2023040307200706000_64.4.611.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.158550"},{"key":"2023040307200706000_64.4.611.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2023040307200706000_64.4.611.8","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","article-title":"First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Zang","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.10","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","article-title":"Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors","volume":"29","author":"Wang","year":"2018","journal-title":"Bioconjug Chem."},{"key":"2023040307200706000_64.4.611.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242263"},{"key":"2023040307200706000_64.4.611.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023040307200706000_64.4.611.13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13550-022-00922-x","article-title":"A pilot study of 68Ga-PSMA-617 PET\/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"EJNMMI Res."},{"key":"2023040307200706000_64.4.611.14","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","article-title":"Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617","volume":"47","author":"Ferdinandus","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.15","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","article-title":"Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"49","author":"Rosar","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.12.055"},{"key":"2023040307200706000_64.4.611.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.057307"},{"key":"2023040307200706000_64.4.611.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263072"},{"key":"2023040307200706000_64.4.611.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2023040307200706000_64.4.611.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.209841"},{"key":"2023040307200706000_64.4.611.21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol."},{"key":"2023040307200706000_64.4.611.22","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.7150\/thno.35759","article-title":"Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617","volume":"9","author":"Kessel","year":"2019","journal-title":"Theranostics."},{"key":"2023040307200706000_64.4.611.23","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1007\/s00259-021-05383-3","article-title":"The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00259-020-04797-9","article-title":"Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)","volume":"48","author":"Ahmadzadehfar","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262552"},{"key":"2023040307200706000_64.4.611.26","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","article-title":"[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: a VISION substudy [abstract]","volume":"40","author":"Kuo","year":"2022","journal-title":"J Clin Oncol."},{"key":"2023040307200706000_64.4.611.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2023040307200706000_64.4.611.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.001"},{"key":"2023040307200706000_64.4.611.29","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2023040307200706000_64.4.611.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.216820"},{"key":"2023040307200706000_64.4.611.31","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"2023040307200706000_64.4.611.33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","article-title":"Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer","volume":"46","author":"Grubm\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023040307200706000_64.4.611.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.260836"},{"key":"2023040307200706000_64.4.611.35","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:23:29Z","timestamp":1680517409000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.2967\/jnumed.122.264857"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264857","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}